Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Teddy Kosoglou

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Drug Safety|April 6, 2007
Mometasone furoate nasal spray: a review of safety and systemic effectsMyron Zitt, Teddy Kosoglou, James Hubbell
Current Medical Research and Opinion|September 24, 2004
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteersLarisa Reyderman, Teddy Kosoglou, Tanya Boutros, et al.
Chest|September 15, 2009
Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axisTeddy Kosoglou, David L Cutler, Heribert Staudinger, et al.
Current Medical Research and Opinion|August 9, 2005
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibeLarisa Reyderman, Teddy Kosoglou, David L Cutler, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjectsTeddy Kosoglou, James Hubbell, Bhavna Kantesaria, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 5, 2026
MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied IndicationsMehrdad Javidi, Gregory E Alexander, Teddy Kosoglou, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler deviceTeddy Kosoglou, James Hubbell, Amy O Johnson-Levonas, et al.
Clinical Pharmacokinetics|May 6, 2005
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactionsTeddy Kosoglou, Paul Statkevich, Amy O Johnson-Levonas, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trialTeddy Kosoglou, Thomas L Hunt, Fengjuan Xuan, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 26, 2013
Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary diseaseTeddy Kosoglou, James Hubbell, Fengjuan Xuan, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Drug Safety|April 6, 2007
Mometasone furoate nasal spray: a review of safety and systemic effectsMyron Zitt, Teddy Kosoglou, James Hubbell
Current Medical Research and Opinion|September 24, 2004
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteersLarisa Reyderman, Teddy Kosoglou, Tanya Boutros, et al.
Chest|September 15, 2009
Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axisTeddy Kosoglou, David L Cutler, Heribert Staudinger, et al.
Current Medical Research and Opinion|August 9, 2005
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibeLarisa Reyderman, Teddy Kosoglou, David L Cutler, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjectsTeddy Kosoglou, James Hubbell, Bhavna Kantesaria, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 5, 2026
MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied IndicationsMehrdad Javidi, Gregory E Alexander, Teddy Kosoglou, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler deviceTeddy Kosoglou, James Hubbell, Amy O Johnson-Levonas, et al.
Clinical Pharmacokinetics|May 6, 2005
Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactionsTeddy Kosoglou, Paul Statkevich, Amy O Johnson-Levonas, et al.
Clinical Pharmacology in Drug Development|April 30, 2016
Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trialTeddy Kosoglou, Thomas L Hunt, Fengjuan Xuan, et al.
International Journal of Chronic Obstructive Pulmonary Disease|March 26, 2013
Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary diseaseTeddy Kosoglou, James Hubbell, Fengjuan Xuan, et al.
Pageof 4